Overview

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide therapy. Following determination of the maximally tolerated or effective dose, cohort expansion will occur to confirm effect on symptoms and safety profile.

Phase:

Phase 2

Details

Lead Sponsor:

Lexicon Pharmaceuticals

Treatments:

Octreotide